AE summary in all exposed patients
| N (%) of patients with ≥1 AE . | N = 88 . |
|---|---|
| Any AE | 84 (95.5) |
| Most common AEs (≥20%) | |
| Neutropenia∗ | 24 (27.3) |
| CRS† | 23 (26.1) |
| Fatigue | 23 (26.1) |
| Rash | 19 (21.6) |
| Any mosunetuzumab-related AE | 69 (78.4) |
| Any grade 3 to 4 AE | 51 (58.0) |
| Most common grade 3 to 4 AEs (≥5%) | |
| Neutropenia∗ | 19 (21.6) |
| Hypophosphatemia | 10 (11.4) |
| Anemia | 8 (9.1) |
| Febrile neutropenia | 5 (5.7) |
| Any mosunetuzumab-related grade 3 to 4 AE | 37 (42.0) |
| Any grade 5 AEs (not including PD)‡ | 3 (3.4) |
| Any mosunetuzumab-related grade 5 AE | 1 (1.1) |
| Any AE leading to discontinuation of mosunetuzumab | 4 (4.5) |
| Any mosunetuzumab-related AE leading to discontinuation of mosunetuzumab | 2 (2.3) |
| Any AE leading to mosunetuzumab dose modification | 1 (1.1) |
| Any AE leading to mosunetuzumab dose interruption | 22 (25.0) |
| N (%) of patients with ≥1 AE . | N = 88 . |
|---|---|
| Any AE | 84 (95.5) |
| Most common AEs (≥20%) | |
| Neutropenia∗ | 24 (27.3) |
| CRS† | 23 (26.1) |
| Fatigue | 23 (26.1) |
| Rash | 19 (21.6) |
| Any mosunetuzumab-related AE | 69 (78.4) |
| Any grade 3 to 4 AE | 51 (58.0) |
| Most common grade 3 to 4 AEs (≥5%) | |
| Neutropenia∗ | 19 (21.6) |
| Hypophosphatemia | 10 (11.4) |
| Anemia | 8 (9.1) |
| Febrile neutropenia | 5 (5.7) |
| Any mosunetuzumab-related grade 3 to 4 AE | 37 (42.0) |
| Any grade 5 AEs (not including PD)‡ | 3 (3.4) |
| Any mosunetuzumab-related grade 5 AE | 1 (1.1) |
| Any AE leading to discontinuation of mosunetuzumab | 4 (4.5) |
| Any mosunetuzumab-related AE leading to discontinuation of mosunetuzumab | 2 (2.3) |
| Any AE leading to mosunetuzumab dose modification | 1 (1.1) |
| Any AE leading to mosunetuzumab dose interruption | 22 (25.0) |